Bluebird Bio Inc (BLUE)

[Moose412]

B-thal and Sickle, hotly contested. CALD, not so much. Dual unanimous recommendations for 1 and 3, sickle (2) in the winter/spring - plus undisclosed pipeline.

Between the option layouts (at current time) and the way this slides on the daily - eh. This 'always something' will (hopefully) see a curtailing of the daily tight elasticity BLUE trades through. GS is not going to have a problem or delay in placing this, I'm sure, although I'll also say I'll never bank w GS again (security breach on their end, certainly nowhere near this level of commerce).

I also see an analyst rating hit-job - but it is biotech, and e're'bodi gotta work.

Not sitting, but not planning on selling anytime soon. What I do expect is to see a 4 word mantra played out hard - Dip to Trip (prints out), it Rips they Flip. $2.4999 might print in the next two weeks, but I doubt it.

Good luck getting back in - if one goes out. It kinda looks like a dead cat bounce - but I'm sure it isn't. I'll jump on $3.00 if it happens. And I'll tell those able to hear.

Please mind the gap.